Celltrion continues to establish its frontrunner position in the omalizumab biosimilar race as the firm submits a biologic license application to the US Food and Drug Administration for its CT-P39, an interchangeable biosimilar candidate to Genentech/Novartis’ Xolair.
The application includes all indications that Xolair is approved for such as asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous